Technical Analysis for ATRX - Adhera Therapeutics Inc.

Grade Last Price % Change Price Change
grade D 0.24 9.09% 0.0200
ATRX closed up 9.09 percent on Tuesday, May 21, 2019, on 1 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical ATRX trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 9.09%
Calm After Storm Range Contraction 9.09%
Narrow Range Bar Range Contraction 9.09%
New 52 Week Low Weakness 9.09%
Wide Bands Range Expansion 9.09%

Older signals for ATRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adhera Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. Its clinical development programs include IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Durham, North Carolina.
Chemistry Biopharmaceutical Pain Chemical Compounds Organic Compounds Hypertension Arthritis Colorectal Cancer Treatment Of Hypertension Nonsteroidal Anti Inflammatory Drugs Pyrazoles
Is ATRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 0.55
52 Week Low 0.22
Average Volume 7,706
200-Day Moving Average 0.0
50-Day Moving Average 0.3427
20-Day Moving Average 0.2841
10-Day Moving Average 0.2512
Average True Range 0.0259
ADX 22.61
+DI 35.1657
-DI 26.547
Chandelier Exit (Long, 3 ATRs ) 0.3023
Chandelier Exit (Short, 3 ATRs ) 0.2977
Upper Bollinger Band 0.3719
Lower Bollinger Band 0.1963
Percent B (%b) 0.25
BandWidth 61.809222
MACD Line -0.0327
MACD Signal Line -0.0298
MACD Histogram -0.0029
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.2400
Resistance 3 (R3) 0.2400 0.2400 0.2400
Resistance 2 (R2) 0.2400 0.2400 0.2400 0.2400
Resistance 1 (R1) 0.2400 0.2400 0.2400 0.2400 0.2400
Pivot Point 0.2400 0.2400 0.2400 0.2400 0.2400
Support 1 (S1) 0.2400 0.2400 0.2400 0.2400 0.2400
Support 2 (S2) 0.2400 0.2400 0.2400 0.2400
Support 3 (S3) 0.2400 0.2400 0.2400
Support 4 (S4) 0.2400